Person:
ŞİMŞEK, MELİH

Loading...
Profile Picture
Status
Organizational Units
Organizational Unit
Job Title
First Name
MELİH
Last Name
ŞİMŞEK
Name
Email Address
Birth Date

Search Results

Now showing 1 - 10 of 14
Loading...
Thumbnail Image
PublicationOpen Access

Diagnostic performance of apparent diffusion coefficient values for the differentiation of intrahepatic cholangiocarcinoma from gastrointestinal adenocarcinoma liver metastases

2021-12-22T00:00:00Z, Yilmaz, TEMEL FATİH, Gultekin, Mehmet Ali, Turk, Hacı Mehmet, Cesme, Dilek Hacer, Besiroglu, Mehmet, Simsek, Melih, Toprak, Huseyin, Alkan, ALPAY, YILMAZ, TEMEL FATİH, TÜRK, HACI MEHMET, ÇEŞME, DİLEK HACER, ŞİMŞEK, MELİH, ALKAN, ALPAY, TOPRAK, HÜSEYİN

Background: We aimed to investigate whether there is a difference between intrahepatic cholangiocarcinoma (IHCC) and liver metastases of gastrointestinal system (GIS) adenocarcinoma in terms of apparent diffusion coefficient (ADC) values. Patients and methods: From January 2018 to January 2020, we retrospectively examined 64 consecutive patients with liver metastases due to gastrointestinal system adenocarcinomas and 13 consecutive IHCC in our hospital's medical records. After exclusions, fifty-three patients with 53 liver metastases and 10 IHCC were included in our study. We divided the patients into two groups as IHCC and liver metastases of GIS adenocarcinoma. For mean apparent diffusion coefficient (ADCmean) values, the region of interests (ROI) was placed in solid portions of the lesions. ADCmean values of groups were compared. Results: The mean age of IHCC group was 62.50 ± 13.49 and mean age of metastases group was 61.15 ± 9.18. ADCmean values were significantly higher in the IHCC group compared to the metastatic group (p < 0.001). ROC curves method showed high diagnostic accuracy (AUC = 0.879) with cut-off value of < 1178 x 10-6 mm2/s for ADCmean (Sensitivity = 90.57, Specificity = 70.0, positive predictive value [PPV] = 94.1, negative predictive value [NPV] = 58.3) in differentiating adenocarcinoma metastases from IHCC. Conclusions: The present study results suggest that ADC values have a potential role for differentiation between IHCC and GIS adenocarcinoma liver metastases which may be valuable for patient management.

No Thumbnail Available
PublicationMetadata only

The effect of adenosine triphosphate on sunitinib-induced cardiac injury in rats

2020-08-01T00:00:00Z, KARA, ALİ VEYSEL, Aldemir, Mehmet Şerif, Simsek, MELİH, ÖZÇİÇEK, FATİH, MAMMADOV, RENAD, YAZICI, GÜLCE NAZ, SUNAR, MUKADDER, COŞKUN, REŞİT, GÜLABOĞLU, Mine, SÜLEYMAN, HALİS, ŞİMŞEK, MELİH

In this study, we aimed to show the effect of adenosine 5 --triphosphate (ATP) on sunitinib-induced cardiac injury in rats. The rats (n = 30) were divided equally into three groups as sunitinib group (SG), sunitinib plus ATP group (SAG), and healthy group (HG); 2 mg/kg ATP was injected intraperitoneally (ip) to the SAG group. Same volume normal saline as solvent was administered ip to the other two groups. After 1 h, 25 mg/kg sunitinib was applied orally via catheter to stomach in the SAG and SG groups. This procedure was repeated once daily for 5 weeks. At the end of this period, all animals were sacrificed and their cardiac tissue was removed. Malondialdehyde (MDA), total glutathione (tGSH), tumor necrosis factor alpha (TNF-alpha), and nuclear factor kappa B (NF-kappa B) levels in rats- cardiac tissues and troponin I (Tp-I) levels in rats- blood samples were evaluated. Histopathological analysis was also performed in cardiac tissues of the animals. MDA, TNF-alpha, NF-kappa B, and Tp-I levels were higher in the SG group compared to the SAG and HG groups (p < 0.001). tGSH levels of the SG group were lower than the SAG and HG groups (p < 0.001). The structure and morphology of cardiac muscle fibers and blood vessels were normal in the control group. In the SG group, obvious cardiac muscle tissue damage with dilated myofibers, locally atrophic myofibers, and congested blood vessels were observed. In the SAG group, marked amelioration in these findings was observed. We showed this for the first time that ATP administration exerts a protective effect against cardiac effects of sunitinib.

No Thumbnail Available
PublicationMetadata only

A case report of fulminant hepatitis due to ribociclib with confirmed by liver biopsy in breast cancer

2021-06-01T00:00:00Z, TOPÇU, Atakan, YASİN, Ayşe İrem, SHBAIR, ABDALLAH T.M., BEŞİROĞLU, MEHMET, ŞİMŞEK, MELİH, SUCUOĞLU İŞLEYEN, ZEHRA, YURTSEVER, İSMAİL, GÜCİN, ZÜHAL, ŞEKER, Mesut, TÜRK, HACI MEHMET, TOPÇU, ATAKAN, YASİN, AYŞE İREM, SHBAIR, ABDALLAH T.M., BEŞİROĞLU, MEHMET, ŞİMŞEK, MELİH, SUCUOĞLU İŞLEYEN, ZEHRA, YURTSEVER, İSMAİL, GÜCİN, ZÜHAL, ŞEKER, MESUT, TÜRK, HACI MEHMET

Introduction Breast cancer is the most frequently diagnosed cancer in women worldwide. Ribociclib is now frequently used in the treatment of metastatic hormone-positive and human epidermal growth factor receptor 2 (HER 2)-negative breast cancer. Case Report A 54-year-old woman with breast cancer presented at a clinic in November 2017 with multiple lung and bone metastases. After receiving multiple lines of treatment due to disease progression, ribociclib and fulvestrant were initiated. Grade 4 toxicity was observed due to ribociclib during follow-up, and ribociclib was discontinued permanently. Management & Outcome: Given that liver transaminases and bilirubin elevation persisted despite discontinuation of the treatment, other reasons for liver toxicity were investigated. Abdominal MRI showed no liver metastases, although there was acute hepatitis. A liver biopsy was performed to determine the etiology. The pathology result was compatible with drug-induced acute fulminant toxic hepatitis. After liver biopsy, prednisolone treatment was initiated, after which the laboratory findings normalized. Discussion Although there are reported cases showing improvement in liver enzymes after ribociclib discontinuation, in our case, no recovery from hepatotoxicity was noticed. The treatment was changed to another hormonal pathway therapy option, exemestane. To the best of our knowledge, this is the first case in the literature reporting this rare side effect of ribociclib, which is a liver biopsy-proven fulminant hepatitis.

No Thumbnail Available
PublicationMetadata only

Efficacy and safety of trastuzumab emtansine in Her2 positive metastatic breast cancer: real world experience.

2021-05-20T00:00:00Z, Bahçeci, Aykut, Paydaş, Semra, Ak, Naziye, Ferhatoğlu, Ferhat, Saip, Pınar Mualla, Seydaoğlu, Gülşah, Bilici, Mehmet, Şimşek, MELİH, Tekin, Salim Başol, Çalikuşu, Züleyha, Yavuz, Sinan, Şahin, Ahmet Bilgehan, Çubukçu, Erdem, Evrensel, Türkkan, Değirmencioğlu, Serkan, Demiray, Atike Gökçen, Yumuk, Perran Fulden, Alan, Özkan, Çikman, Duygu İlke, Demirelli, Fuat Hulusi, Köstek, Osman, Gökyer, Ali, Doğan, Mutlu, Bal, Öznur, Çakar, Burcu, Gökmen, Erhan, Yamaç, Deniz, Korkmaz, Taner, Aliyev, Altay, Keskin, Özge, Urvay, Semiha, Büyükşimşek, Mahmut, Karadeniz, Cemile, Yildiz, Birol, Yeşil Çinkir, Havva, Demir, Hacer, Beypinar, İsmail, Karaçin, Cengiz, Eser, Kadir, Baykara, Meltem, Kiliçkap, Saadettin, Okutur, Kerem, Bulut, Gülcan, Alkan, Ali, Arpaci, Erkan, Pilanci, Kezban Nur, Demir, Atakan, Işik, Deniz, Yildirim, Nilgün, ŞİMŞEK, MELİH

Loading...
Thumbnail Image
PublicationOpen Access

Breast Cancer Patients with Brain Metastases: A Cross-Sectional Study.

2022-08-19T00:00:00Z, Simsek, MELİH, Aliyev, Altay, Baydas, Tuba, Besiroglu, Mehmet, Demir, Tarik, Shbair, Abdallah Tm, Seker, Mesut, Turk, H Mehmet, ŞİMŞEK, MELİH, TÜRK, HACI MEHMET

The prognosis of breast cancer patients with brain metastasis is poor. It was aimed to define the clinicopathological features of breast cancer patients with brain metastases and to determine the risk factors and survival outcomes associated with brain metastasis. This is a single-center, retrospective, cross-sectional study. A total number of 127 patients diagnosed with breast cancer and who developed brain metastasis between January 2011 and March 2021 were retrospectively analyzed. The survival and clinicopathological data of these patients according to 4 biological subtypes were evaluated (luminal A, luminal B, HER-2 overexpressing, and triple-negative). The median overall survival for all patients was 45.6 months. The median time from the diagnosis of breast cancer to the occurrence of brain metastasis was 29.7 months, and the median survival time after brain metastasis was 7.2 months. The time from the diagnosis of breast cancer to brain metastasis development was significantly shorter in HER-2 overexpressing and triple-negative subtypes than in luminal A and B subtypes. The median time from breast cancer diagnosis to brain metastasis was 33.5 months in luminal A, 40.6 months in luminal B, 16.8 months in HER-2 overexpressing, and 22.8 months in the triple-negative groups (p=0.003). We found the worst median survival after brain metastasis in the triple-negative group with 3.5 months. Early and close surveillance of high-risk patients may help early diagnosis of brain metastasis and may provide to perform effective treatments leading to longer overall survival times for this patient population.

Loading...
Thumbnail Image
PublicationOpen Access

Efficacy and safety profile of COVID-19 vaccine in cancer patients: a prospective, multicenter cohort study

2022-01-01T00:00:00Z, YASİN, Ayşe İrem, Aydin, Sabin Goktas, SÜMBÜL, BİLGE, KORAL, LOKMAN, ŞİMŞEK, MELİH, Geredeli, Caglayan, Ozturk, Akin, Perkin, Perihan, Demirtas, Derya, Erdemoglu, Engin, HACIBEKİROĞLU, İLHAN, Cakir, Emre, Tanrikulu, Eda, Coban, Ezgi, Ozcelik, Melike, Celik, Sinemis, Teker, Fatih, AKSOY, ASUDE, Firat, Sedat T., Tekin, Omer, Kalkan, Ziya, Turken, Orhan, Oven, Bala B., Dane, Faysal, Bilici, Ahmet, Isikdogan, Abdurrahman, ŞEKER, Mesut, TÜRK, HACI MEHMET, Gumus, Mahmut, YASİN, AYŞE İREM, SÜMBÜL, BİLGE, ŞİMŞEK, MELİH, ŞEKER, MESUT, TÜRK, HACI MEHMET

Aim: To compare the seropositivity rate of cancer patients with noncancer controls after inactive SARS-CoV-2 vaccination and evaluate the factors affecting seropositivity. Method: Spike IgG antibodies against SARS-CoV-2 were measured in blood samples of 776 cancer patients and 715 noncancer volunteers. An IgG level ≥50 AU/ml is accepted as seropositive. Results: The seropositivity rate was 85.2% in the patient group and 97.5% in the control group. The seropositivity rate and antibody levels were significantly lower in the patient group (p < 0.001). Age and chemotherapy were associated with lower seropositivity in cancer patients (p < 0.001). Conclusion: This study highlighted the efficacy and safety of the inactivated vaccine in cancer patients.

No Thumbnail Available
PublicationMetadata only

The importance of the glucose-to-lymphocyte ratio in patients with hepatocellular carcinoma treated with sorafenib

2021-08-01T00:00:00Z, YILMAZ, Ali, ŞİMŞEK, MELİH, HANNARİCİ, Zekeriya, Buyukbayram, Mehmet E., BİLİCİ, Mehmet, Tekin, Salim B., ŞİMŞEK, MELİH

Aim: To show the prognostic significance of the glucose-to-lymphocyte ratio (GLR) in hepatocellular carcinoma (HCC). Patients & methods: A total of 150 patients with advanced HCC who were treated with sorafenib in our center between January 2011 and December 2019 were included in the study retrospectively. Neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, lymphocyte-to-monocyte ratio, platelet-to-lymphocyte ratio, prognostic nutritional index and GLR were analyzed to assess their prognostic value using Kaplan-Meier and Cox regression analysis before and after propensity score matching (PSM). Results: In univariate analysis before and after PSM, albumin-bilirubin grade, neutrophil-to-lymphocyte ratio, systemic immune-inflammation index, lymphocyte-to-monocyte ratio, prognostic nutritional index, AFP level and GLR were found to be significantly associated with both progression-free and overall survival. In multivariate analysis before and after PSM, GLR, albumin-bilirubin grade and AFP were determined to be independent prognostic factors for progression-free and overall survival. Conclusion: The GLR prior to sorafenib treatment is a new prognostic biomarker that may predict survival in advanced HCC.

No Thumbnail Available
PublicationMetadata only

Mide kanserli hastaların demografik özelliklerinin sağ kalıma etkisi

2022-05-01T00:00:00Z, Karadeniz, Andaç, Bilici, Mehmet, Şimşek, Melih, ŞİMŞEK, MELİH

No Thumbnail Available
PublicationMetadata only

Metastatic Breast Carcinoma Mimicking Urothelial Carcinoma

2022-06-01T00:00:00Z, Shbair, Abdallah T. M., YASİN, Ayşe İrem, TOPÇU, Atakan, ÇOBAN, GANİME, UZUNOĞLU, GÖKÇE DENİZ, ŞİMŞEK, MELİH, YASİN, AYŞE İREM, TOPÇU, ATAKAN, ÇOBAN, GANİME, UZUNOĞLU, GÖKÇE DENİZ, ŞİMŞEK, MELİH

Besides being the most frequently diagnosed cancer in women, breast cancer is the main cause of cancer-related deaths in this group of patients. Breast cancer frequently metastasizes to bone, lung, brain, and liver. Renal metastasis from the breast is extremely rare. Here we aimed to report a case of breast cancer with metastasis to bone and left renal pelvis. A 58-year old woman with a mass lesion in the left renal pelvis that mimicked urothelial carcinoma was referred to our clinic. The left nephroureterectomy procedure was performed, and the pathology revealed that a renal pelvis metastasis secondary to breast cancer.

No Thumbnail Available
PublicationMetadata only

Pituitary Gland Metastasis of Breast Cancer: A Rare Case Report and Review of the Literature

2020-07-01T00:00:00Z, Şimşek, Melih, ŞİMŞEK, MELİH